Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
复制标题
DOI：
10.1192/bjp.178.3.234
复制
发表时间：
2001-03-01
影响因子：
10.5
通讯作者：
Rudolph, RL
中科院分区：
文献类型：
--
作者：
Thase, ME;Entsuah, AR;Rudolph, RL
研究表明，抗抑郁药文拉法辛可以抑制血清素和（高剂量）去甲肾上腺素的再摄取，可能比选择性血清素再摄取抑制剂（SSRIs）治疗效果更好。目的比较SSRIs或文拉法辛治疗期间的缓解率。方法收集8项可比较的随机双盲研究的数据，比较文拉法辛（n=851）、SSRIs（氟西汀、帕罗西汀、氟伏沙明，n=748）或安慰剂（4项研究，n=446）治疗期间的缓解率（汉密尔顿抑郁量表评分小于或等于7）。结果缓解率为：文拉法辛，45% (382/851)；ssri类，35% (260/748)；安慰剂，25% (110/446)（P < 0.001；缓解的优势比为1.50(1.3-1.9)，支持文拉法辛与SSRIs）。文拉法辛与SSRIs之间的差异在第2周时具有显著性，而SSRIs与安慰剂之间的差异在第4周达到显著性。结果不依赖于任何一项研究或缓解的定义。结论文拉法辛组的缓解率明显高于SSRI组。利益声明M.E.T.是惠氏实验室的有偿顾问，惠氏实验室是A.R.E和R.L.R.的雇主
Background It had been suggested that the antidepressant venlafaxine, which inhibits reuptake of both serotonin and (at higher doses) noradrenaline, may result in better outcomes than treatment with selective serotonin reuptake inhibitors (SSRIs).Aims To compare remission rates during treatment with SSRIs or venlafaxine.Method Data from eight comparable randomised, double-blind studies of major depressive disorder were pooled to compare remission rates (Hamilton Rating Scale for Depression score less than or equal to7) during treatment with venlafaxine (n=851), SSRIs (fluoxetine, paroxetine, fluvoxamine; n=748) or placebo (four studies; n=446).Results Remission rates were: venlafaxine, 45% (382/851); SSRIs, 35% (260/748); placebo, 25% (110/446) (P < 0.001; odds ratio for remission is 1.50 ( 1.3-1.9), favouring venlafaxine v. SSRIs). The difference between venlafaxine and the SSRIs was significant at week 2, whereas the difference between SSRIs and placebo reached significance at week 4. Results were not dependent on any one study or the definition of remission.Conclusions Remission rates were significantly higher with venlafaxine than with an SSRI.Declaration of interest M.E.T. is a paid consultant to Wyeth -Ayerst Laboratories, the employer of A.R.E, and R.L.R.